Navigation Links
Fujirebio Diagnostics Announces FDA Clearance of Lumipulse G whole PTH Assay
Date:11/20/2019

Fujirebio Diagnostics, Inc., a consolidated subsidiary of Miraca Holdings Inc., has received U.S. Food and Drug Administration (FDA) clearance of the company’s Lumipulse® G whole PTH Assay for testing on its LUMIPULSE® G1200 immunoassay platform.

Parathyroid hormone (PTH) is a hormone secreted by the parathyroid glands; which are four small glands located behind the thyroid gland. The hormone regulates metabolism of Calcium and Phosphoric Acid in the body. The measurement of whole Parathyroid Hormone (wPTH or PTH (1-84)) using the Lumipulse® G whole PTH assay can be used in the differential diagnosis of hypercalcemia and hypocalcemia resulting from calcium metabolism disorders.

The Lumipulse® G whole PTH assay has a significant benefit over prior generation intact PTH assays currently used in most laboratories.The measurement of biologically active PTH (1-84) helps to understand parathyroid function without potential misclassification of the patients. There is no detectable cross reactivity to 7-84 and other PTH fragments observed with intact PTH (iPTH) assays; since whole PTH measures only the biologically active PTH and is 100% specific to whole PTH. Intact PTH can overestimate PTH indicated bone/mineral abnormalities because iPTH assays also detect various PTH fragments(1).

For Chronic Kidney Disease (CKD) patients not yet on dialysis (stage 3-5), The Clinical Practice Guideline CKD-MBD, Final Version (1/3/2015) recommends the measurement and monitoring of several tests including PTH as part of patient management. A falsely high PTH measurement due to a second generation iPTH test may result in falsely identifying a patient for dialysis.(2)

The Lumipulse® G whole PTH is also traceable to in-house calibrators that have been assigned to the World Health Organization’s (NIBSC 95/646) standard; while iPTH assays are not standardized and their values can vary by manufacturer.

The Lumipulse® G whole PTH Assay on the Lumipulse® G1200 analyzer offers a fully automated assay with a reaction time of just 30 minutes; using a single test cartridge design for reagent stability, efficiency, and testing flexibility. The assay has demonstrated excellent precision with a CV of =4.0%.

“The Lumipulse® G whole PTH Assay is an innovative next-generation assay to help diagnose Calcium metabolism disorders, and to help monitor and adjust treatment of CKD patients.” says Matthew Bell, Vice President Sales and Marketing at Fujirebio, US.

About Fujirebio Diagnostics, Inc.
Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio Holdings, Inc., is the premier cancer diagnostics company and the industry leader in cancer biomarker assays. The company pioneered and introduced the CA125 test, the first FDA-approved ovarian cancer biomarker over 25 years ago. Fujirebio Diagnostics specializes in the clinical development, manufacturing and commercialization of in-vitro diagnostic products for the management of human disease states, with an emphasis in oncology. For more information about Fujirebio Diagnostics, please call +1 610-240-3800 or visit us at https://www.fujirebio.com/en.

About Fujirebio
Fujirebio is a global leader in the field of high quality in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products. Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions.

Fujirebio is today a member of Miraca Group (Miraca Holdings Inc. listed on the Tokyo Stock Exchange – TYO: 4544) and employs more than 1,200 people in Asia, Europe and America.

(1) Kazama, J, Intact PTH assay overestimates true 1-84 PTH levels after maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism, Nephrology Dialysis Transplantation (2004) 19:892-897
(2) Priolo, G. Comparison between whole and intact Parathyroid Hormone assays, FRE-117, May 2017

Read the full story at https://www.prweb.com/releases/fujirebio_diagnostics_announces_fda_clearance_of_lumipulse_g_whole_pth_assay/prweb16681269.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine news :

1. Companion Diagnostics Market (Breast Cancer, Lung Cancer, Colorectal Cancer, etc.) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
2. India In Vitro Diagnostics (IVD) Market Analysis and 2018 Forecasts in New Research Report at MarketReportsOnline.com
3. Global In Vitro Diagnostics Market - Industry Analysis, Size, Share, Growth and Forecast, 2012 - 2018
4. BCC Research Publishes a New Report On Global Markets for Companion Diagnostics
5. UK Clinical Chemistry and Immunodiagnostics Market Opportunities Discussed in New VPG Report Published at MarketPublishers.com
6. Zamansky LLC Comments On the Settlement By Quest Diagnostics And LabCorp. Of America Of The Whistle-Blower Lawsuit
7. Health Briefs TV Offers a View on Diagnostics Segment
8. Molecular Diagnostics Role in Cancer Testing Analyzed in In-demand TriMark Report Published at MarketPublishers.com
9. Global In Vitro Diagnostics (IVD) Market 2013
10. Industry Analysis, Size, Share, Growth, Trends and Forecast Research Report Available Online by Researchmoz.us
11. Holographic diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2019)... ... November 21, 2019 , ... Desert Pines Equine Medical ... national network of veterinary practices. The deal closed on September 20th, 2019. , ... Winchell, DVM at Desert Pines Equine Medical & Surgical Center. “We are on our ...
(Date:11/22/2019)... (PRWEB) , ... November 21, 2019 , ... ... that it has received DEA approval to ship THC and CBD from Canada. ... derivatives from the marijuana plant containing THC and CBD. MMJ will be utilizing ...
(Date:11/22/2019)... (PRWEB) , ... November 22, 2019 , ... Acclaimed actor ... the educational show “Behind The Scenes”. The program functions as a teaching tool for ... In a new episode of “Behind The Scenes,” viewers are taken on a journey ...
(Date:11/21/2019)... ... November 21, 2019 , ... Susan G. Komen Chicago Executive ... in the category of Maverick of the Year in the 16th Annual Stevie® Awards ... Award in the category of Organization of the Year (Government or Non-Profit with 10 ...
(Date:11/21/2019)... ... November 21, 2019 , ... Google disclosed 1 ... and therefore, AllKindsofTherapy.com average session length is two minutes. Treatment programs ... therapist is licensed, clinical hours with clients, and types of evidence-based treatments or ...
Breaking Medicine News(10 mins):
(Date:12/4/2019)... ... December 04, 2019 , ... Intelligent.com, ... the Top 17 Master's in Organizational Psychology Degree Programs for 2020. The comprehensive ... in the nation. Each program is evaluated based on curriculum quality, graduation rate, ...
(Date:12/2/2019)... ... December 02, 2019 , ... ... healthier places to live, work, learn, and play. Striving to fulfill their crucial ... the rigorous national standards set by the Public Health Accreditation Board (PHAB). Today, ...
(Date:11/30/2019)... ... 29, 2019 , ... In the United States, we regard chefs as a ... there is no shortage of phenomenal restaurants for guests to visit. Meet the chef ... world. Christian Bowman, Chef to NBA All-Stars and celebrities, is a culinary master with ...
Breaking Medicine Technology: